Gelonghui, December 29 | Recco Biotech (02179.HK) announced today that its self-developed new adjuvant recombinant herpes zoster vaccine REC610 achieved positive results in a clinical study using GSK Shingrix as a positive control. Data analyzed during the study period showed that two doses of REC610 were generally safe and well tolerated in healthy subjects aged 40 and above. Rec610 can induce strong GE-specific humoral immune and cellular immune responses. Immune response occurs immediately after the first dose and peaks 30 days after the two doses. Its level is comparable to that of the Shingrix group, and is numerically higher than that of the Shingrix group. The shingrix vaccine developed by the multinational pharmaceutical company GSK has excellent protective efficacy. It has been rapidly released since its launch in 2017. It has been ranked in the top ten best-selling vaccine varieties in the world all year round, with annual global revenue of nearly 3 billion pounds in 2022. Shingles is a common viral infectious disease. According to statistics, there are about 6 million cases of shingles in China every year, and the incidence of shingles is gradually getting younger in recent years. REC610 was independently developed by Recobiology and is intended to be used to prevent shingles in adults aged 40 and above. According to statistics, the number of people aged 40 and above in China is about 700 million. The new adjuvant recombinant vaccine is only marketed by GSK Shingrix, and there is a strong demand for import substitution.